Orthocell CEO and MD, Paul Anderson, hosted a webinar this morning to provide an important update on Orthocell’s clinical and commercial plans.
Watch the replay:
Thailand Regulatory Application for Remplir™
Orthocell has submitted a regulatory application to the FDA of Thailand to commence sales of its groundbreaking nerve repair device Remplir™, with clearance expected in Q3 CY2025.
Orthocell Submits Canada Regulatory Application to Commence Sales of Remplir™ into US$75million Canadian market
Orthocell has announced it has submitted an application to Health Canada for a Medical Device Licence (MDL) to sell its leading nerve repair product Remplir™ into the US$75 million Canadian nerve repair market.
Stockhead | Orthocell soars 14% after crushing early sales growth for Remplir
Orthocell’s plans to broaden its commercial footprint in existing and new markets drove the company’s share price up 13.8% this week, according to a special report in Stockhead.
Orthocell Accelerates Global Expansion: Five New Country Regulatory Submissions Planned in 2025
On the back of outstanding early sales traction for Remplir™ in Australia, New Zealand and Singapore, Orthocell has announced that it is accelerating its global expansion into multiple key jurisdictions.
Orthocell receives $3.18m R&D tax incentive refund
Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year.
Stockhead Special Report | Orthocell achieves third consecutive quarter of record revenue
Orthocell has been featured in a special report on Stockhead highlighting Orthocell’s consistent growth in sales of our regenerative medicine products, Striate+ and Remplir.
OCC Quarterly Report | Quarter ended 31 December 2024
Orthocell has recorded a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter.
Podcast | Talk Ya Book
Orthocell Chairman John Van Der Wielen recently spoke with podcast host Chris Judd on Talk Ya Book to discuss the Company’s journey and exciting plans for global expansion with its regenerative medicine technologies.
The West Australian | Orthocell cracks a new record high
Orthocell has been featured in The West Australian in an article by Sean Smith titled “Orthocell cracks a new record high.”